Published in Ocular Surface

How Recognizing and Treating the Ocular Surface Improves My Contact Lens Practice

This is editorially independent content supported by advertising from Bausch + Lomb
4 min read

Sit down with Drs. Mark Schaeffer and Adam Ramsey as they discuss how to distinguish between and treat ocular surface and contact lens discomfort.

In this episode of Inside Intrepid, Mark Schaeffer, OD, FAAO, sits down with Adam Ramsey, OD, to discuss why contact lens discomfort and ocular surface disease must be evaluated and treated together.
They outline how a targeted patient history, a deliberate treatment sequence, and an upfront commitment check reduce repeat lens rechecks and improve retention.

"If we're not addressing the surface, we're just kicking that can down the road."—Mark Schaeffer, OD, FAAO

Contact lens wear and the ocular surface: fast facts

  • Contact lens discomfort (CLD) affects an estimated 35 to 58% of wearers and is a leading cause of lens discontinuation.1
  • Contact lens-associated dry eye (CLADE) persists with preexisting ocular surface disease; contact lens-induced dry eye (CLIDE) resolves after lens wear stops.1
  • Up to 70% of contact lens wearers report mild-to-severe dry eye symptoms, and approximately 25% score in the severe range on the Ocular Surface Disease Index (OSDI).1
  • The Tear Film & Ocular Surface Society (TFOS) Lifestyle report found that lens wear can exacerbate disease morbidity in eyes with a pre-existing compromised ocular surface.2
  • A 2026 metagenomic and proteomic analysis found no significant differences in ocular surface microbiome composition or in the tear proteome between soft lens wearers and non-wearers, although female wearers reported higher OSDI scores.3
  • In a 30-day phase 4 open-label trial, perfluorohexyloctane instilled before and during lens wear improved Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) scores by day 7, with continued gains and longer comfortable wear time through day 30; current labeling directs patients to remove lenses before instillation.4
  • Treating meibomian gland dysfunction (MGD) in lens wearers can extend comfortable wear time by 4 hours per day.5

Treating the lens and the surface as one problem

Both clinicians argue that refitting a symptomatic patient without evaluating the ocular surface addresses only part of the problem. Time spent on history and surface assessment at the first visit replaces the third and fourth lens rechecks that would otherwise follow a lens-only approach.

Start with the eye, not the lens

Dr. Ramsey asks how the eyes feel on waking, after lens removal, and on days spent in glasses. Dryness that precedes insertion points to the surface. For patients who never go without lenses, he prescribes glasses for one day per week or a few hours daily to give the cornea a break.
Onset timing is his main discriminator. Lens-associated dry eye symptoms characteristically worsen with prolonged wear and toward the end of the day,1 while discomfort within minutes of insertion implicates the lens itself.

"If you find them [contact lenses] uncomfortable within five minutes of putting them in, that could be the contact. At the end of the day, that's dryness; your body is not producing enough moisture on the cornea."—Adam Ramsey, OD

Upgrade first, or treat concurrently?

The two diverge on sequencing. Dr. Ramsey refits into a single-use silicone hydrogel lens, rechecks in 10 to 14 days, and layers over-the-counter or prescription therapy only if morning or end-of-day symptoms persist.

"I would never add a treatment without upgrading the lens first, because now I'm making them do a treatment in perpetuity."—Adam Ramsey, OD

Dr. Schaeffer upgrades the lens and treats the surface at the same visit, citing evidence that surface therapy itself extends wear time.
In a multicenter randomized trial of 55 soft lens wearers with MGD and evaporative dry eye, a single vectored thermal pulsation treatment produced the following versus untreated controls:5
  • Mean meibomian gland secretion score change of 12.4 ± 9.1 vs. 1.4 ± 6.4 at 3 months (P < 0.0001)
  • Mean Standard Patient Evaluation of Eye Dryness (SPEED) score change of −8.4 ± 4.7 vs −0.7 ± 4.4 at 3 months (P < 0.0001)
  • Mean comfortable wear time increased by 4.0 ± 3.9 hours per day at 1 month, sustained through 3 months with no change in controls
The trial was open label, and its lead author was employed by the device manufacturer.5
If the patient is experiencing ongoing issues with a second lens change and discomfort with multiple lenses of the same category, Dr. Schaeffer considers these to be red flags. It’s important to address these concerns to help the patient reach their desired outcome.

Confirm commitment before prescribing

Before recommending a twice-daily drop, Dr. Ramsey asks whether the patient would actually use it. Hesitation suggests the patient is venting, not asking for a change.
A stated commitment and scheduled recheck have lowered his no-show rate; he reports that 90% of his lens patients wear daily disposables, and 85% purchase annual supplies. Dr. Schaeffer adds that this same buy-in makes the prior authorization and education workload required for a prescription worthwhile.

In closing

Both clinicians treat persistent lens discomfort as a potential surface problem until proven otherwise.
A brief history focused on symptom timing and lens-free comfort separates the two causes, and an explicit commitment question predicts whether therapy will be sustained. Whether surface treatment follows a lens upgrade or accompanies it, addressing both reduces repeat visits and keeps patients in lenses.

To learn how optometrists are managing their contact lens practices in 2026, download our 2026 Contact Lens Report.

This article was produced by our editorial team in collaboration with subject-matter experts. AI may have been used as an editorial tool under the direction of human editors, who reviewed and approved all content.

Want this episode in podcast form? Subscribe to Inside Intrepid on your favorite podcasting platforms!

  1. Abdelaziz O, Ghalibafan S, Ruiz-Lozano RE, et al. Contact lens-associated ocular surface and corneal disorders. Methods Protoc. 2026;9(3):95. doi:10.3390/mps9030095
  2. Jones L, Efron N, Bandamwar K, et al. TFOS Lifestyle: Impact of contact lenses on the ocular surface. Ocul Surf. 2023;29:175-219. doi:10.1016/j.jtos.2023.04.010
  3. Kopp OS, Morandi SC, Kreuzer M, et al. Impact of contact lenses on the ocular surface microbiome, tear proteome, and dry eye disease. Microbiol Spectr. 2026;14(3):e0226425. doi:10.1128/spectrum.02264-25
  4. Cooper J. Instilling Miebo during contact lens wear may reduce ocular discomfort. Healio. September 30, 2026. Accessed November 5, 2026. https://www.healio.com/news/optometry/20260930/instilling-miebo-during-contact-lens-wear-may-reduce-ocular-discomfort.
  5. Blackie CA, Coleman CA, Nichols KK, et al. A single vectored thermal pulsation treatment for meibomian gland dysfunction increases mean comfortable contact lens wearing time by approximately 4 hours per day. Clin Ophthalmol. 2018;12:169-183. Published 2018 Jan 17. doi:10.2147/OPTH.S153297
Mark Schaeffer, OD, FAAO
About Mark Schaeffer, OD, FAAO

Dr. Mark Schaeffer serves as Clinical Excellence Captain at MyEyeDr in Birmingham, Alabama where he practices full-scope optometry. In addition to his clinical work, he is affiliated with several pharmaceutical companies in consulting for ocular disease and contact lenses. Dr. Schaeffer is the author of multiple articles that have appeared in various journals. He has served as a moderator for EyeTubeOD and has given several COPE-approved presentations. He is a founding member of the Intrepid Eye Society and is a member of the Alabama and American Optometric Association, American Academy of Optometry, and the Contact Lens and Cornea Section.

Dr. Schaeffer earned a Bachelor of Business Administration in Marketing from University of Georgia, his Doctor of Optometry from Southern College of Optometry, and completed a residency in Ocular Disease at Bascom Palmer Eye Institute in Miami, Florida.

Mark Schaeffer, OD, FAAO
Adam Ramsey, OD
About Adam Ramsey, OD

Dr. Ramsey graduated Cum Laude from the University of Florida, he went on to Southern College of Optometry where he obtained his Doctorate of Optometry. Dr. Ramsey is the owner of Socialite Vision Eye Care with Style.

Dr. Ramsey is a board-certified Optometrist who is the past board chairman of the Palm Beach Optometric Association and past vice president of the T Leroy Jefferson Medical Association. Dr. Ramsey is an internationally known and respected published author, speaker consultant, researcher, and advisor.

Over the past few years, Dr. Ramsey has made it his mission to help with the issue of diversity and inclusion in the eye care space. In 2019, he co-founded Black Eyecare Perspective, a nonprofit organization designed to cultivate lifelong relationships between African Americans and the eye care industry. In May 2022, Dr. Ramsey was awarded the New England College of Optometry Presidential Medal for his work through Black Eyecare Perspective.

Adam Ramsey, OD
💙 Inside Intrepid
Orasis Pharmaceuticals
Bausch + Lomb Xiidra
Bausch + Lomb Miebo
TenPoint - Yuvezzi
Thea Pharma, Inc.
Alcon, Inc.